Myrlene Sanon

Myrlene Sanon

Auto-generated profile, based on publicly available information

Myrlene Sanon

Johnson & Johnson Horsham Pennsylvania USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in Kidney Medicine
Verified
Journal Article
Open access
SMSteven N. Michalopoulos
Steven N. Michalopoulos
MGMarjolaine Gauthier-Loiselle
Marjolaine Gauthier-Loiselle
MAMyrlene Sanon Aigbogun
Myrlene Sanon Aigbogun
ESElizabeth Serra
Elizabeth Serra
RBRebecca Bungay
Rebecca Bungay
JWJay Wish
Jay Wish
Chronic kidney disease (CKD) has a far-reaching impact on both patients and care partners, which can be further compounded by frequent complications such as anemia. This study assessed the burden experienced by patients with CKD and the care partners of patients with CKD, with and without anemia. Online survey. Adult patients with CKD and the care partners of adult patients with CKD living in the United States were recruited through the American Association of Kidney Patients and a third-party online panel (January 9, 2020-March 12, 2020). Patient and care partner characteristics, care received or provided; health-related quality of life, and work productivity. Descriptive statistics were reported separately based on the presence or absence of anemia. In total, 410 patients (anemia: n=190, no anemia: n=220) and 258 care partners (anemia: n=110, no anemia: n=148) completed the survey. Most patients reported receiving paid or unpaid care because of their health condition (anemia: 58.9%, no anemia: 50.9%), with an overall average of 14.2 and 11.3 h/wk among the anemia and no anemia patients, respectively. The care partners also reported providing numerous hours of care (anemia: 33.6 h/wk, no anemia: 38.0 h/wk), especially care partners living with their care recipient (anemia: 52.6 h/wk, no anemia: 42.8 h/wk). Among the patients, those with anemia reported a numerically lower average health-related quality of life (Functional Assessment of Cancer Therapy-Anemia score, anemia: 110.1; no anemia: 121.6). Most care partners reported a severe or very severe burden (Burden Scale for Family Caregivers-Short Version score≥15, anemia: 69.1%; no anemia: 58.8%). The work productivity impairment was substantial among employed patients (anemia: 44.9%, no anemia: 35.4%) and employed care partners (anemia: 47.9%, no anemia: 40.7%). The survey results may have been subject to selection and recall biases; moreover, the observational nature of the study does not allow for causal inferences. Patients with CKD and the care partners of patients with CKD experience a considerable burden, especially when anemia is present.

28 June 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
KRKenneth Rockwood
Kenneth Rockwood
MAMyrlene Sanon Aigbogun
Myrlene Sanon Aigbogun
JSJustin Stanley
Justin Stanley
HWHelen Wong
Helen Wong
TDTaylor Dunn
Taylor Dunn
RBRoss A Baker
Ross A Baker
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

6 May 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
TDTim Disher
Tim Disher
DNDominik Naessens
Dominik Naessens
MSMyrlene Sanon
Myrlene Sanon
ABAshley Bonner
Ashley Bonner
JEJenna Ellis
Jenna Ellis
ADAxel Dignass
Axel Dignass
Introduction This study used network meta-analysis (NMA) to evaluate the comparative efficacy of available advanced therapies for moderately to severely active Crohn’s disease (CD) versus the IL-23 inhibitor guselkumab. Methods A systematic literature review was conducted to identify randomized controlled trials (RCTs) of advanced therapies in moderately to severely active CD. Bayesian NMAs were conducted for outcomes of clinical response, clinical remission, endoscopic response, and a combined outcome of clinical remission with endoscopic response, at the end of the maintenance phase (up to 1 year). Primary analyses included patients with varied prior inadequate treatment responses, with additional analyses conducted for specific subgroups. Re-randomized trials were normalized in several cases to mimic a standard treat-through design, incorporating data from additional sources, when necessary, for patients who had an inadequate response or experienced a delayed response following induction. Results Of the 58 RCTs identified, 13 with maintenance endpoint data were ultimately included in the NMAs. Guselkumab 100 mg and 200 mg were more likely to be effective versus several comparators. Guselkumab 200 mg demonstrated significantly greater efficacy versus infliximab 10 mg/kg every 8 weeks and upadacitinib 30 mg daily for clinical response and clinical remission. For endoscopic response, guselkumab 200 mg showed significantly greater efficacy than ustekinumab, adalimumab, and upadacitinib. Significance was also noted versus ustekinumab on the combined outcome of clinical remission with endoscopic response. Similarly, guselkumab 100 mg demonstrated efficacy versus comparators across analyses. Guselkumab achieved higher rankings based on surface under the cumulative ranking curve. Findings of primary analyses within mixed populations were generally corroborated by subpopulation analyses. Conclusion Results of this NMA in moderately to severely active CD indicate a higher likelihood of guselkumab achieving each clinical and endoscopic endpoint analyzed at the end of the maintenance phase versus other advanced therapies assessed.

2 December 2025 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
KYKaung Yan
Kaung Yan
SVSudheer Kumar Vuyyuru
Sudheer Kumar Vuyyuru
ATAdam Taylor
Adam Taylor
GFGrazziela Figueredo
Grazziela Figueredo
TRTim Raine
Tim Raine
GMGordon W. Moran
Gordon W. Moran
Background and Aims: It is unclear if a sustained response to the first advanced therapy affects the long-term risk of hospitalization in patients with inflammatory bowel disease (IBD). We have undertaken a retrospective analysis of clinical outcomes using the National Institute for Health and Care Research (NIHR) IBD BioResource database. Methods: We included adult patients (≥18 years old) with Crohn disease (CD) or ulcerative colitis (UC) who received treatment with at least 1 advanced therapy. Treatment response was defined as clinical response or remission for 12 months or longer. The outcome was the incidence of IBD-related long-term risk of hospitalization, defined as admission for IBD-related surgery or disease exacerbation requiring intravenous corticosteroids over the duration of follow-up. Results: A total of 15 531 patients (CD, 10 024; and UC, 5507) were included in the analysis. Overall, 82% of CD patients and 75.2% of UC patients experienced treatment response to their first advanced treatment. Treatment response to the first advanced therapy initiated was significantly associated with a lower long-term risk of hospitalization in both CD (odds ratio [OR], 0.826; 95% CI, 0.797-0.857) and UC (OR, 0.975; 95% CI, 0.954-0.997). The median (IQR) time (years) for hospitalization In CD responders was 2 (1-4) years and in CD nonresponders was 1.17 (1-3) years, P < .0001 and in UC responders was 1.38 (0.85-3) years and in UC nonresponders was 1 (0.65-2) years, P < .0019. Conclusions: Treatment response to the first advanced treatment initiated is significantly associated with a lower long-term risk of hospitalization for IBD. Choosing the best therapy the first time may improve long-term outcomes.

29 November 2024 in Crohn's & Colitis 360
Verified
Journal Article
Open access
JKJim Kershaw
Jim Kershaw
MSMyrlene Sanon
Myrlene Sanon
SKSumesh Kachroo
Sumesh Kachroo
SBSophie Barlow
Sophie Barlow
DNDominik Naessens
Dominik Naessens
THTimothy Hoops
Timothy Hoops
Background: Despite a wide range of available treatments, there is limited evidence as to why significant numbers of Crohn’s disease (CD) patients do not achieve disease remission or continue to have residual symptom burden. We aimed to quantify the impact of this suboptimal treatment on patient symptom incidence and severity, quality of life (QoL), and work impairment. Methods: Data were derived from the Adelphi Real World CD Disease Specific Programme, a cross-sectional survey of CD patients and their treating physicians in France, Germany, Italy, Spain, the United Kingdom, and the United States between January 2020 and March 2021. Physicians reported on patients’ clinical history, disease status, symptom load, and treatment. Patients reported their QoL and activity impairment using the EQ-5D-5L and Work Productivity and Activity Impairment measures. Patients were divided into remitters, partial remitters, and non-remitters. Multivariate regression models were used to assess the impact of remission status on clinical and QoL outcomes. Results: Of 1786 patients, 24.1% were remitters, 53.2% were partial remitters, and 22.7% were non-remitters. Partial remitters and non-remitters had a significantly higher symptom load than remitters (P < .05), and non-remitters were up to 15 times more likely to experience key symptoms than remitters. Both non-remitters and partial remitters were also significantly more likely to have increased symptom severity (P < .05). Non-remitters were more likely to have switched treatment and received more treatment lines, as well as having significantly worse QoL, than remitters. Conclusions: Suboptimal treatment response was associated with increased symptoms and QoL burden. Despite the increased burden experienced, partial remitters were not more likely to switch or receive more treatment lines than remitters, demonstrating the need to initiate effective therapy.

5 February 2026 in JCC Plus
Verified
Journal Article
Open access
MSMyrlene Sanon
Myrlene Sanon
SNShanti Neff‐Baro
Shanti Neff‐Baro
AGAline Gauthier
Aline Gauthier
DNDominik Naessens
Dominik Naessens
MVMarion L. Vetter
Marion L. Vetter
BFBrian Feagan
Brian Feagan
Background and Aims: Achieving endoscopic response (ER), defined as a > 50% reduction from baseline in Simple Endoscopic Score for Crohn's disease (SES‐CD) score, following induction therapy for Crohn's disease (CD) has been linked to improved 1‐year outcomes. We evaluated the impact of ER at the end of maintenance (EOM) on long‐term clinical outcomes. Methods: Data from a Phase 3 randomized trial (IM‐UNITI, ustekinumab) and a Phase 2 trial (GALAXI 1, guselkumab and ustekinumab) were analyzed using multivariable statistical methods. The relationship between ER at the EOM (Week 48) and outcomes at Week 96, including clinical remission, hospitalization, and surgery, was assessed. Results: Endoscopic and clinical remission data at the EOM were available for 461 patients. ER at EOM was significantly associated with higher odds of clinical remission (odds ratio [OR] = 1.91; p < 0.05) at Week 96. ER was also linked to reduced inflammatory burden, with higher odds of C‐reactive protein normalization (OR = 2.19; p < 0.005). Forty‐one patients were hospitalized or required surgery during the long‐term extension, with higher event rates among those without ER at the EOM ( p = 0.1237). Conclusions: ER after 48 weeks of maintenance therapy was associated with a greater likelihood of clinical remission and improved quality of life at 1 year. Data also suggest lower hospitalization and surgery rates for those who achieve ER. Larger studies are needed to substantiate long‐term reductions in hospitalizations and surgeries.